NCT02318277 - A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | Biotech Hunter

Enrollment

176

Participants

Timeline

Start Date

January 5, 2015

Primary Completion Date

August 28, 2019

Study Completion Date

October 16, 2020

Conditions

Solid TumorsHead and Neck CancerLung CancerUC (Urothelial Cancer)

Interventions

DRUG

MEDI4736

MEDI4736 administered intravenously (IV) every two weeks (q2w)

DRUG

INCB024360

INCB024360: Oral daily dosing

Trial Locations (13)

San Francisco

Denver

Miami

Port Saint Lucie

Sarasota

Tampa

Chicago

Louisville

Durham

Huntersville

Winston-Salem

Dallas

Houston